GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » Net Income (Continuing Operations)

Suven Pharmaceuticals (BOM:543064) Net Income (Continuing Operations) : ₹3,003 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Suven Pharmaceuticals's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was ₹534 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹3,003 Mil.


Suven Pharmaceuticals Net Income (Continuing Operations) Historical Data

The historical data trend for Suven Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals Net Income (Continuing Operations) Chart

Suven Pharmaceuticals Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Income (Continuing Operations)
Get a 7-Day Free Trial 3,170.02 3,623.42 4,538.05 4,112.90 3,002.81

Suven Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,239.71 1,205.90 795.64 467.54 533.73

Suven Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,003 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suven Pharmaceuticals  (BOM:543064) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Suven Pharmaceuticals Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Pharmaceuticals (BOM:543064) Business Description

Traded in Other Exchanges
Address
3rd Floor, Road No. 5, Avenue 7, Banjara Hills, No. 8-2-334, SDE Serene Chambers, Hyderabad, TG, IND, 500034
Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.

Suven Pharmaceuticals (BOM:543064) Headlines

No Headlines